Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Programmed cellular immunotherapeutic - Fate Therapeutics

Next Previous
Search
Drug Profile

Programmed cellular immunotherapeutic - Fate Therapeutics

Alternative Names: FT1050/FT4145 - modulated mobilised peripheral blood; Programmed mobilised peripheral blood cells; ProTmune FT1050/FT4145 programmed mobilised peripheral blood; ProTmune™

Latest Information Update: 13 May 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Scripps Research Institute
  • Developer Fate Therapeutics
  • Class Cell therapies; Haematopoietic stem cells therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cytomegalovirus infections; Graft-versus-host disease

Most Recent Events

  • 13 May 2021 Discontinued - Phase-II for Graft-versus-host disease (Prevention) in USA (Parenteral)
  • 05 May 2021 Discontinued - Phase-II for Cytomegalovirus infections (Prevention) in USA (Parenteral)
  • 05 May 2021 Fate Therapeutics completes the phase I/II PROTECT trial for Graft-versus-host disease and Cytomegalovirus infections (Prevention) in USA (NCT02743351)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top